L
Locana
Creating a new class of gene therapies by targeting disease-causing messenger RNA
About Locana
Locanabio is a biotechnology startup that operates in the healthcare sector, specifically in the field of genetic medicine. The company's primary focus is on developing RNA-targeted gene therapies to treat rare diseases caused by genetic mutations. These mutations result in disease-causing RNA transcripts, which Locanabio's platform targets and modifies, potentially correcting the disease at its source.
Read full description
The company's business model revolves around the research, development, and commercialization of these gene therapies. They generate revenue through the successful development and subsequent sale of these therapies to healthcare providers. Their clients are primarily healthcare institutions and patients suffering from rare genetic diseases.
Locanabio is also involved in the presentation of preclinical data and participates in various conferences and meetings related to genetic medicine. This suggests a commitment to continuous research and development, as well as a desire to stay at the forefront of the field. The company also values partnerships and collaborations, indicating a potential for future growth and expansion.
In terms of social responsibility, Locanabio emphasizes diversity and inclusion within its company culture. They also offer career opportunities for those interested in making a positive difference in the lives of patients with rare genetic diseases.
At a glance
- Status
- Operational
- Founded
- 2016
- Headquarters
- San Diego, United States
- Employees
- 7
- Open positions
- None listed
- Dealroom signal
- 65.7/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Neurology, Genetics and genomics, Degenerative Diseases, RNA, Spinout, Biotech and Pharma, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| LATE VCOther financing | May 2023 | $0 | — | CureDuchenne Ventures | ↗ |
| SERIES BOther financing | Dec 2020 | $100M | $400M | Lightstone Ventures · RA Capital Management · Vida Ventures · Temasek | — |
Growth signals
Latest recorded traffic for Locana is 1.1K monthly website visits, up 31% over the last three months. Locana's team declined 12.5% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A8 investors entered at this stage
ARCH Venture Partners
Temasek
Lightstone Ventures
Vida Ventures
RA Capital Management- APAcuta Capital Partners
UCB Ventures
SVB Leerink
Series B and later1 investor entered at this stage
CureDuchenne Ventures
Other known investors1 additional known investor
University of California, San Diego
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Locana on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Locana’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.